期刊文献+

ppar-α激动剂的虚拟筛选研究 被引量:2

Study on Virtual Screening of ppar-α Agonists
下载PDF
导出
摘要 通过虚拟筛选分子对接技术,利用sc-PDB数据库得到蛋白靶点的5类共晶结构。采用vina程序,基于建立的小分子数据库,分别对5类共晶结构进行对接计算。通过重对接过程,计算rmsd(均方根偏差值)来评估利用vina程序是否适用于该体系,通过构建诱饵化合物以及小分子与蛋白的相互作用分析来验证了模型的可靠程度。最终,利用该模型分别对5个靶点进行虚拟筛选,得到了效果较为理想的7个动剂分子,分析了分子和靶点蛋白的作用模式。 Through the virtual screening of molecular docking technology, 5 kinds of eutectic structure of protein target were obtained by sc-PDB database. Based on the established small molecule database, 5 kinds of eutectic structures were calculated by vina program. Through re docking process, RMSD (root mean square deviation value ) was calculated to assess whether the vina program was applicable to the system. The reliability of the model was verified by the analysis of the interaction between the decoy compounds and the small molecules with the protein. 5 targets were screened by the model, and 7 ideal molecules were obtained. The mode of action of molecular and target protein was analyzed.
作者 罗蓓 郭银应 陈双扣 任玉婷 LUO Bei;GUO Yin-ying;CHEN Shuang-kou;REN Yu-ting(School of Chemistry and Chemical Engineering, Chongqing University of Science and Technology,Chongqing, 401331, China)
出处 《广州化工》 CAS 2019年第7期49-51,54,共4页 GuangZhou Chemical Industry
基金 工业发酵微生物重庆市重点实验室开放基金:酪氨酸蛋白激酶抑制剂的定量构效关系及虚拟筛选研究(LIFM201710) 重庆科技学院研究生科技创新项目:NASH药物PPAR双重激动剂的虚拟筛选及分子设计(YKJCX1720512)
关键词 ppar-α激动剂 分子对接 ROC曲线 虚拟筛选 ppar-α agonist molecular docking ROC curve virtualscreening
  • 相关文献

参考文献8

二级参考文献71

  • 1LIU Ailin, CAO Hongpeng & DU Guanhua Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China,Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.Drug screening for influenza neuraminidase inhibitors[J].Science China(Life Sciences),2005,48(1):1-5. 被引量:7
  • 2YEPing WANGZhao-jun ZHANGXiu-jin ZHAOYa-li.Age-related decrease in expression of peroxisome proliferator-activated receptor α and its effects on development of dyslipidemia[J].Chinese Medical Journal,2005(13):1093-1098. 被引量:9
  • 3石如玲,姜玲玲.胆汁酸对大鼠肝脏过氧化物酶体增殖剂激活受体αmRNA表达的影响[J].河北医科大学学报,2005,26(5):368-369. 被引量:2
  • 4Guan Y, Breyer MD. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.Minerva Urol Nefrol, 2002,54: 65 ~79.
  • 5Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int, 2001,60: 14~30.
  • 6Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes. Drug News and Perspective, 2002,15: 147 ~ 154.
  • 7Desvergene B, Wahli W. Peroxisome proliferator-activated receptor: nuclear control of metabolism. Endocr Rev, 1999,20: 649 ~ 688.
  • 8Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic.Circulation, 2003,108: 1552~ 1553.
  • 9Koh EH, Kim MS, Park JY, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats:comparison with PPAR-gamma activation. Diabetes,2003, 52: 2331 ~2337.
  • 10Diep QN,Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension,2000,36: 851 ~855.

共引文献117

同被引文献23

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部